Full video transcriptClick to expand
Auto-generated transcript of @kodi_dyel's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00What are the best fat burners coming from a body building coach?
- 0:03Well, I'll talk to you guys about a couple.
- 0:04See me guys like the last video, I'll break down a couple more things here.
- 0:06So you have to look at it like this.
- 0:08They're all in different categories.
- 0:09We have like enhanced, natural, either way you'll find both of them in the bio with
- 0:12code die, with genuine peptides or evil gen.
- 0:15Now, talking about the enhanced ones, we all know the GOP ones.
- 0:17We know like the Ozenpik, retitruitide, trizepartide, those three are up there.
- 0:22Now, Ozenpik and trizepartide are mostly just appetite suppressants versus retitruitide
- 0:26as the fat burning effects and it has the hunger suppression.
- 0:29So it's kind of the best of both worlds.
- 0:30That's my go to at the moment.
- 0:31A lot of people like that.
- 0:33Next you have like this stimulant based fat burning, which is like clan or like a Tesso
- 0:36fin scene.
- 0:37Clan feels kind of like an energy drink, but it just lasts a couple hours and nothing too
- 0:40crazy for most people.
- 0:41Besides like the shaky hands is not fun.
- 0:44Getting into the Tesso fin scene, it doesn't seem as effective in my personal opinion compared
- 0:47to clan, but you feel very happy, very jolly.
- 0:50The downside though, when you come off, if you stop just cold turkey, there's like this
- 0:53really weird come down period, really like you're super happy and then you're unhappy
- 0:57and then you start feeling normal after a week or two.
- 0:59So that definitely happens.
- 1:01Then you have like the T3 and T4, which is like more so your thyroid med does an entirely
- 1:04different topic, but typically they do get thrown in there.
- 1:07If you're someone who just doesn't have a super fast metabolism, they get utilized every
- 1:10once in a while, but we don't need it.
- 1:12Keep in mind you abuse that your body cannot differentiate between fat loss and muscle loss.
- 1:16You could eat your muscle up with the quickness if you abuse those too long and too high of
- 1:20a dosage.
- 1:21Now there are some other options like the AOD or some GW or Tesso Morrell and they all work
- 1:26relatively well, but at the end of the day, there's not too many things that's ever going
- 1:29to beat like a clan in T3.
- 1:30They've been king and bodybuilding for as long as they could remember.
- 1:33Then of course you have the natural options.
- 1:35You have like the Ocarnotene, CLAs, you'll him bind anything of that nature, not magic,
- 1:38but it could work.
- 1:39At least you'll him by works really well.
- 1:41You'll him by an HCL or alpha you'll him by.
- 1:43Either way, code DYEL in the bio for anything enhanced and natural.
GLP-1 drugs and bodybuilding: what contest prep coaches get wrong
Quick answer
This video recommends a mix of FDA-approved GLP-1 medications, unapproved research compounds, and veterinary drugs for fat loss in a bodybuilding context, with an affiliate sales incentive throughout. Retatrutide's superior efficacy signal in phase 2 trials is real, but several compounds mentioned, including GW-501516 and AOD-9604, have no approved human use and meaningful safety concerns. Anyone considering GLP-1 therapy for weight management should pursue it through a licensed prescriber who can assess cardiovascular history, contraindications, and appropriate dosing, not through a peptide vendor affiliate link.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and bodybuilding: what contest prep coaches get wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 drugs and bodybuilding: what contest prep coaches get wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and bodybuilding: what contest prep coaches get wrong" from Kodi DYEL. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video recommends a mix of FDA-approved GLP-1 medications, unapproved research compounds, and veterinary drugs for fat loss in a bodybuilding context, with an affiliate sales incentive throughout.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to redain caije teamdyel personaltrainer onlinefitn." In this clip, the useful excerpt is: "What are the best fat burners coming from a body building coach?" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video recommends a mix of FDA-approved GLP-1 medications, unapproved research compounds, and veterinary drugs for fat loss in a bodybuilding context, with an affiliate sales incentive throughout.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video recommends a mix of FDA-approved GLP-1 medications, unapproved research compounds, and veterinary drugs for fat loss in a bodybuilding context, with an affiliate sales incentive throughout. Retatrutide's superior efficacy signal in phase 2 trials is real, but several compounds mentioned, including GW-501516 and AOD-9604, have no approved human use and meaningful safety concerns. Anyone considering GLP-1 therapy for weight management should pursue it through a licensed prescriber who can assess cardiovascular history, contraindications, and appropriate dosing, not through a peptide vendor affiliate link.
- Retatrutide showed approximately 24% body weight reduction in Jastreboff et al. (2023, NEJM) phase 2 trials, but it is not yet FDA-approved and cannot be legally prescribed for general weight loss.
- GW-501516 (Cardarine) caused rapid multi-organ tumor growth in animal studies and was abandoned before human trials. There is no established safe dose for humans.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide showed approximately 24% body weight reduction in Jastreboff et al. (2023, NEJM) phase 2 trials, but it is not yet FDA-approved and cannot be legally prescribed for general weight loss.
- GW-501516 (Cardarine) caused rapid multi-organ tumor growth in animal studies and was abandoned before human trials. There is no established safe dose for humans.
- Clenbuterol is not FDA-approved for human use. Documented adverse effects include cardiac arrhythmias and electrolyte imbalances, not just hand tremors.
- Tesofensine never reached market approval. Its triple monoamine reuptake inhibition produces real withdrawal effects on discontinuation, not just a mild mood dip.
- T3 misuse suppresses the hypothalamic-pituitary-thyroid axis. Endogenous thyroid function may not recover fully after prolonged supraphysiologic dosing.
- Yohimbine has modest but real evidence for fat mobilization via alpha-2 adrenergic blockade. It is the one natural compound in this video with legitimate mechanistic support.
- All GLP-1 medications mentioned, including semaglutide and tirzepatide, require a prescription and clinical evaluation. Sourcing them through peptide vendors bypasses the safety infrastructure that exists for good reason.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @kodi_dyel actually say?
An IFBB-affiliated bodybuilding coach ranked fat burners into "enhanced" and "natural" categories, naming retatrutide as superior to semaglutide and tirzepatide because it offers "fat burning effects" alongside hunger suppression. He also recommended clenbuterol, tesofensine, T3/T4 thyroid medications, and peptides like AOD-9604 and GW-501516. He wrapped up with natural options including L-carnitine, CLA, and yohimbine, pushing an affiliate code throughout.
This is a bodybuilding coach selling affiliate products while casually discussing prescription medications, unapproved research compounds, and controlled substances in the same breath. That context matters.
Does the science back this up?
Parts of it do, parts of it are oversimplified, and some of it involves compounds that have no business being recommended to general audiences. The GLP-1 framing is the most defensible section. The rest gets shakier fast.
On GLP-1s: semaglutide and tirzepatide are FDA-approved and well-studied. Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors) and early phase 2 data published by Jastreboff et al. (2023, NEJM) showed roughly 24% body weight reduction over 48 weeks, which is genuinely impressive. The claim that retatrutide has direct "fat burning effects" beyond appetite suppression is an oversimplification. The glucagon component does increase energy expenditure, but calling it a separate fat-burning mechanism versus the others is a marketing-friendly framing, not a clean scientific distinction.
Clenbuterol: it is a beta-2 agonist used in veterinary medicine, not approved for human use in the U.S. Tremors, cardiac arrhythmias, and electrolyte disturbances are well-documented risks (Spiller et al., 2013, Clinical Toxicology). Describing it as feeling "like an energy drink" dramatically undersells the risk profile.
Tesofensine: a triple monoamine reuptake inhibitor. Phase 2 trials (Astrup et al., 2008, The Lancet) showed meaningful weight loss, but its development stalled partly due to cardiovascular concerns. The "come down" he describes is real and maps onto noradrenergic withdrawal. Calling it a mood crash after stopping "cold turkey" is accurate but framed too casually for something with genuine psychiatric implications.
T3/T4: thyroid hormones are prescription medications. The warning about muscle catabolism is accurate and supported by physiology. But mentioning these alongside affiliate codes normalizes misuse.
What did they get wrong (or right)?
He got the retatrutide mechanism directionally right, even if the explanation was loose. He also correctly flagged that T3 abuse causes muscle loss, not just fat loss, which is a real and underappreciated risk in bodybuilding communities.
What he got wrong: the framing that GW-501516 (Cardarine) "works relatively well" is a serious problem. GW-501516 is a PPARdelta agonist that was abandoned in preclinical development because it caused rapid cancer growth in animal studies (Peraza et al., 2006, Toxicological Sciences). It has never been approved for human use. Recommending it casually as a fat burner in a TikTok video is irresponsible, full stop.
AOD-9604 is an unapproved peptide fragment. It failed its clinical trials for obesity and was never approved by the FDA. Lumping it in with "works relatively well" is not supported by evidence.
Yohimbine: the one natural compound he actually undersold. Alpha-2 antagonism does have some evidence behind it, particularly in stubborn fat areas (Ostojic, 2006, Research in Sports Medicine). His description is reasonable.
What should you actually know?
If you're considering any of the compounds mentioned in this video, the risk ladder is steep and the regulatory picture is clear. Semaglutide and tirzepatide are FDA-approved for weight management under specific indications. Retatrutide is still in trials and not available through legitimate prescribers for general weight loss. Clenbuterol is not approved for human use in the U.S. Tesofensine never made it to market. GW-501516 was shelved because it caused cancer in animals.
The affiliate code structure here means the creator has a direct financial interest in you purchasing these compounds. That does not make everything he says wrong, but it is a conflict of interest that should inform how you weigh his recommendations.
For GLP-1 medications specifically, access through a regulated telehealth platform means a licensed prescriber reviews your health history and determines whether you are an appropriate candidate. That step exists for a reason. None of the compounds in this video should be sourced from peptide vendors without a prescription and clinical oversight.
- Retatrutide's phase 2 results are real, but it is not available as a legal prescription drug yet.
- GW-501516 (Cardarine) has preclinical carcinogenicity data. Do not use it.
- Clenbuterol is associated with serious cardiac events in humans, not just shaky hands.
- T3 suppresses endogenous thyroid function. Recovery is not guaranteed after long-term misuse.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kodi DYEL · TikTok creator
11.1K views on this video
Replying to @Redain Caije #teamdyel #personaltrainer #onlinefitnesscoach #gymtok #contestprep #showprep #ifbbpro #gymmotivation #gymlife #fitnessjourney #coachesoftiktok #fatloss #gymlife
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about retatrutide showed approximately 24% body weight reduction in jastreboff et?
Retatrutide showed approximately 24% body weight reduction in Jastreboff et al. (2023, NEJM) phase 2 trials, but it is not yet FDA-approved and cannot be legally prescribed for general weight loss.
What does the video say about gw-501516 (cardarine) caused rapid multi-organ tumor growth in animal studies?
GW-501516 (Cardarine) caused rapid multi-organ tumor growth in animal studies and was abandoned before human trials. There is no established safe dose for humans.
What does the video say about clenbuterol?
Clenbuterol is not FDA-approved for human use. Documented adverse effects include cardiac arrhythmias and electrolyte imbalances, not just hand tremors.
What does the video say about tesofensine never reached market approval. its triple monoamine reuptake inhibition?
Tesofensine never reached market approval. Its triple monoamine reuptake inhibition produces real withdrawal effects on discontinuation, not just a mild mood dip.
What does the video say about t3 misuse suppresses the hypothalamic-pituitary-thyroid axis. endogenous thyroid function may?
T3 misuse suppresses the hypothalamic-pituitary-thyroid axis. Endogenous thyroid function may not recover fully after prolonged supraphysiologic dosing.
What does the video say about yohimbine has modest?
Yohimbine has modest but real evidence for fat mobilization via alpha-2 adrenergic blockade. It is the one natural compound in this video with legitimate mechanistic support.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kodi DYEL, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.